2474-P: Comparable Hepatic Benefits with Differential Effects on Triglycerides and Glycemic Control: A 24-Week Prospective Study
DINESH KUMAR, Harshita Lachhwani, MUKULESH GUPTA, Kumar Prafull Chandra et autres
Introduction and Objective: Metabolic Associated Steatotic Liver Disease (MASLD) frequently coexists with type 2 diabetes mellitus (T2DM) and obesity and represents a major unmet clinical need, particularly with respect to therapies that improve both hepatic and metabolic outcomes. Comparative data between saroglitazar …